Literature DB >> 18227478

Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.

Zvonko Milicevic1, Itamar Raz, Scott D Beattie, Barbara N Campaigne, Samiha Sarwat, Elwira Gromniak, Irina Kowalska, Edvard Galic, Meng Tan, Markolf Hanefeld.   

Abstract

Atherosclerotic vascular disease is more common in diabetic than in nondiabetic individuals. Diabetic macrovascular disease also has a more severe course with greater prevalence of multiple-vessel coronary artery disease and more diffuse elongated atheromas in affected blood vessels. In this review, we discuss possible reasons for increased incidence of cardiovascular (CV) events in individuals with diabetes. Although an increased prevalence of standard CV risk factors has been clearly documented in association with diabetes, diabetes-related abnormalities, particularly hyperglycemia, also play an important role. Epidemiological studies suggest that the effect of hyperglycemia on CV risk is independent of other known risk factors, but no data from primary interventional trials are available yet. Analysis of datasets from populations that included individuals with impaired glucose tolerance and impaired fasting glucose suggest that the pathogenic role of hyperglycemia on the blood vessel wall already exists in the early stages of glucose intolerance. The effect of postprandial or postchallenge hyperglycemia seems to be greater than the effect of fasting blood glucose abnormalities. The relationship of postprandial glycemia, fasting blood glucose, and CV risk in individuals with diagnosed (or overt) diabetes is less clear, although most reports indicate a greater pathogenic potential of postprandial hyperglycemia rather than fasting hyperglycemia. Based on the results of epidemiological reports, the most appropriate targets in interventional trials are postprandial hyperglycemia or A1C.

Entities:  

Mesh:

Year:  2008        PMID: 18227478     DOI: 10.2337/dc08-s240

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  37 in total

1.  Prevalence, types and factors associated with echocardiographic abnormalities among newly diagnosed diabetic patients at Mulago Hospital.

Authors:  Martin Muddu; Edrisa Mutebi; Charles Mondo
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

Review 2.  Association between genetics of diabetes, coronary artery disease, and macrovascular complications: exploring a common ground hypothesis.

Authors:  André G Sousa; Lívia Selvatici; José E Krieger; Alexandre C Pereira
Journal:  Rev Diabet Stud       Date:  2011-08-10

Review 3.  Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.

Authors:  J Grams; W Timothy Garvey
Journal:  Curr Obes Rep       Date:  2015-06

4.  Serum C-reactive protein level and prediabetes in two Asian populations.

Authors:  C Sabanayagam; A Shankar; S C Lim; J Lee; E S Tai; T Y Wong
Journal:  Diabetologia       Date:  2011-01-26       Impact factor: 10.122

5.  Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions.

Authors:  Jorge R Miranda-Massari; José R Rodríguez-Gómez; Michael J González; Carlos Cidre; Jorge Duconge; Heriberto Marín; Kazuko Grace; Howard L McLeod
Journal:  Int J Diabetes Res       Date:  2016

6.  12S-hydroxyeicosatetraenoic acid levels link to coronary artery disease in Type 2 diabetic patients.

Authors:  H J Zhang; C H Sun; H Y Kuang; X Y Jiang; H L Liu; W F Hua; Z J Liu; H Zhou; H Sui; R Qi
Journal:  J Endocrinol Invest       Date:  2012-10-22       Impact factor: 4.256

7.  Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.

Authors:  Robert Krysiak; Anna Gdula-Dymek; Ryszard Bachowski; Boguslaw Okopien
Journal:  Diabetes Care       Date:  2010-06-29       Impact factor: 19.112

8.  TCF7L2 polymorphism rs7903146 is associated with coronary artery disease severity and mortality.

Authors:  André Gustavo P Sousa; Guilherme F Marquezine; Pedro A Lemos; Eulogio Martinez; Neuza Lopes; Whady A Hueb; José E Krieger; Alexandre C Pereira
Journal:  PLoS One       Date:  2009-11-17       Impact factor: 3.240

Review 9.  Shifting the disease management paradigm from glucose: what are the pros?

Authors:  Alin Stirban; Diethelm Tschoepe; Bernd Stratmann
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

10.  The natural protective mechanism against hyperglycemia in vascular endothelial cells: roles of the lipid peroxidation product 4-hydroxydodecadienal and peroxisome proliferator-activated receptor delta.

Authors:  Yael Riahi; Yoav Sin-Malia; Guy Cohen; Evgenia Alpert; Arie Gruzman; Juergen Eckel; Bart Staels; Michel Guichardant; Shlomo Sasson
Journal:  Diabetes       Date:  2010-01-27       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.